

Reference: FOI.ICB-2627/045

Subject: Autism and ADHD Assessments and IAP Provider Allocation

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
Please provide the following information in relation to neurodevelopmental services (Autism and ADHD) commissioned or funded by your Integrated Care Board:	
1. Independent Sector Provision a. Please provide a list of all independent providers currently: • contracted, • accredited, or • otherwise delivering services (including on a non-contracted or ad hoc basis) - Any provider that invoiced for activity in March 2026 to undertake Autism and/or ADHD assessments on behalf of the ICB.	Bristol, North Somerset and South Gloucestershire (BNSSG) ICB holds a contract for children and young people (CYP) and adult ADHD and Autism assessment and Treatment services with Clinical Partners. BNSSG ICB have accredited Clinical Partners for the services listed above. One provider has passed accreditation subject to contract mobilisation and once the contract is issued, the award notice will be published as per Provider Selection Regime (PSR) rules. The below is the list of ADHD & Autism Independent Sector providers who invoiced us for activity in March 2026: • ADHD 360 LTD • ATROM MINDCARE LIMITED • CENTRE FOR ADHD RESEARCH AND EXCELLENCE (THE)

	• EVOLVE PSYCHOLOGY SERVICES LTD • HELP 4 PSYCHOLOGY SERVICES LTD • JAJAWI & ASKER LTD • KIRSOP TAYLOR HEALTHCARE LTD • MIND PROFESSIONALS LIMITED • OWL CENTRE LTD (THE) • PSICON LTD • PSYCH-UK LTD • RTN MEDICAL LTD • RTN MENTAL HEALTH SOLUTIONS LTD • SKYLIGHT PSYCHIATRY LTD • TELEDOTOR LTD
2. Indicative Activity Plan (IAP) Allocation a. Please provide a list of providers and the total Indicative Activity Plan (IAP) allocation assigned to each provider for the 2026/27 financial year. b. For each provider, please provide a breakdown of the IAP allocation, where available, including: - Autism assessments - ADHD assessments - ADHD medication initiation, titration, and review services c. Where possible, please further distinguish the above activity by: • Adults • Children and Young People (CYP)	a. Providers in scope of Indicative Activity Plans in 2026-27 are: • ADHD 360 • Atrom Mindcare • CARE ADHD • Clinical Partners • Dr J & Colleagues • Evolve Psychology • Harrow Health CIC • Health Harmonie Minds • Held Health • KT Healthcare • Paloma Health • Problem Shared • Psicon

- Psychiatry UK
- RTN Medical
- RTN Mental Health Solutions
- Skylight Psychiatry Ltd

Please refer to response to b. below regarding IAP allocations.

- b. In line with previous requests of this nature, recently [FOI.ICB-2526/402: Right to Choose Framework for Adult ADHD and Autism Assessments](#):

The ICB has applied Section 43(2) to this question where further information regarding IAPs has been requested. Section 43(2) exempts from disclosure information which would, or would likely to, prejudice the commercial interests of any legal person (an individual, a company, the public authority itself or any other legal entity). Section 43(2) is a qualified exemption and therefore subject to the public interest test. The public interest arguments in favour of disclosing information include the ICB's responsibility to be transparent and accountable in its decision making and to promote public understanding of processes. The ICB has considered that the expenditure and any variance within these is funded through public funds and therefore there is a public interest in how this money is spent and whether it constitute value for money. The ICB discharges its duty by monthly publishing of all spend over £25,000 and this is available on the ICB website:

	https://bnssghealthiertogether.org.uk/library/icb-spend-over-25000-january-2026/ The public interest argument in favour of maintaining the exemption include direction from the finance team at the ICB that these IAPs underpin the basis of ICB contracts and therefore cannot be shared outside the ICB as these are commercially sensitive. Disclosure of these activity plans and the associated activity and financials would disadvantage the ICB when commissioning future contracts and IAPs. Pricing is often a critical factor in decision making for services. The ICB has a responsibility to secure the best use of public resources and provide value for money and to achieve this, the ICB needs to be able to develop IAPs without disclosure to ensure that confidential pricing information and activity is not disclosed. This information would give providers a commercial advantage. The ICB has considered both arguments and believes that maintaining the exemption is in the public's interest as it supports the ICB to commission services which are value for money. c. Please see response to b. above.
--	---

The information provided in this response is accurate as of 23 June 2026 and has been approved for release by Caroline Dawe - Deputy Director of Performance and Delivery, Acute and Integrated Care, MHLDA and EPRR and Jenny Bowker - Deputy Director of Performance Delivery, Primary Care and Children's Services for NHS Bristol, North Somerset and South Gloucestershire ICB.